AI-Enabled HYDROS Robotic System Launches Internationally, Expanding Aquablation Therapy Access
PRCT sits 41% above its 52-week low of $19.35 on elevated volume (2.4× avg).
Summary
PROCEPT BioRobotics has announced the international launch of its HYDROS Robotic System, an AI-enabled platform for Aquablation therapy, with the UK marking the initial expansion and further international growth planned for 2026. This strategic move directly supports the company's growth trajectory, building on the strong 37% revenue growth reported in its recent fiscal year 2025 10-K. The introduction of this advanced robotic system globally is a material step in expanding market access for its core BPH treatment, leveraging AI and robotic precision to drive future revenue and solidify its position in the urology market. This development is a positive catalyst for continued business expansion.
At the time of this announcement, PRCT was trading at $27.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $19.35 to $66.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.